COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review.
COVID-19
SARS-CoV-2
immune checkpoint inhibitors
immune-related adverse events
immunotherapy
Journal
Journal of immunotherapy and precision oncology
ISSN: 2590-017X
Titre abrégé: J Immunother Precis Oncol
Pays: United States
ID NLM: 101768397
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
25
08
2022
revised:
16
12
2022
accepted:
21
12
2022
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) can cause inflammatory and immune-related adverse events (irAEs) that might worsen the course of COVID-19. We conducted a systematic review (PROSPERO ID: CRD42022307545) to evaluate the clinical course and complications of COVID-19 in patients with cancer receiving ICI. We searched Medline and Embase through January 5, 2022. We included studies evaluating patients with cancer who received ICI and developed COVID-19. Outcomes included mortality, severe COVID-19, intensive care unit (ICU) and hospital admissions, irAEs, and serious adverse events. We pooled data with random effects meta-analysis. Twenty-five studies met study eligibility ( Although current evidence is limited, COVID-19 clinical outcomes of patients with cancer receiving ICI therapy appear to be similar to those not receiving oncologic treatment or other cancer therapies.
Identifiants
pubmed: 37214207
doi: 10.36401/JIPO-22-24
pmc: PMC10195019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103-110Subventions
Organisme : NCI NIH HHS
ID : K08 CA237619
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Déclaration de conflit d'intérêts
Conflict of interest: Dr. Suarez-Almazor has received consultant fees in the past 12 months from Pfizer, Eli Lilly, and Bristol Myers Squibb/Celgene, unrelated to this study.
Références
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Cancer. 2021 Jan 15;127(2):266-274
pubmed: 33112411
Int Immunopharmacol. 2021 Dec;101(Pt A):108242
pubmed: 34688136
Oncologist. 2021 May;26(5):e898-e901
pubmed: 33783099
Int J Dermatol. 2021 Jan;60(1):e30-e32
pubmed: 33040324
Cancer Rep (Hoboken). 2021 Oct;4(5):e1388
pubmed: 34014037
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Cancer Immunol Immunother. 2022 Feb;71(2):373-386
pubmed: 34173850
Ann Oncol. 2021 May;32(5):674-676
pubmed: 33600920
JAMA Oncol. 2022 Jan 1;8(1):69-78
pubmed: 34709356
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Eur J Cancer. 2020 Aug;135:251-259
pubmed: 32540204
Front Med (Lausanne). 2021 Feb 16;8:604221
pubmed: 33665196
J Clin Oncol. 2021 Jul 10;39(20):2232-2246
pubmed: 34085538
Sci Rep. 2021 Mar 1;11(1):4814
pubmed: 33649382
J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):689-690
pubmed: 28552623
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Can J Kidney Health Dis. 2021 May 19;8:20543581211014745
pubmed: 34046182
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
ESMO Open. 2020 Nov;5(Suppl 3):
pubmed: 33158968
Cancer. 2020 Oct 1;126(19):4294-4303
pubmed: 32729142
J Thorac Oncol. 2020 Nov;15(11):1767-1772
pubmed: 32653627
Eur J Cancer. 2020 Aug;135:242-250
pubmed: 32586724
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33593827
Curr Oncol Rep. 2020 May 8;22(5):53
pubmed: 32385672
Nat Cancer. 2020 Oct;1(10):965-975
pubmed: 35121871
Acta Oncol. 2021 Jan;60(1):13-19
pubmed: 33131376
SN Compr Clin Med. 2021;3(6):1412-1415
pubmed: 33824942
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Immunotherapy. 2021 Oct;13(15):1271-1282
pubmed: 34431319
Eur J Cancer. 2021 Feb;144:382-385
pubmed: 33342623